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ABSTRACT 
 
Endoglin (CD105) is an auxiliary membrane receptor of transforming growth 
factor- (TGF-) that interacts with type I and type II TGF- receptors and modulates 
TGF- signalling. Mutations in endoglin are involved in Hereditary Hemorrhagic 
Telangiectasia type I, a disorder characterized by cutaneous telangiectasias, epistaxis 
(nosebleeds) and major arteriovenous shunts, mainly in liver and lung. Endoglin is 
overexpressed in the tumor-associated vascular endothelium where it modulates 
angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer 
therapy. Recent studies on human and experimental models of carcinogenesis point to 
an important tumor cell-autonomous role of endoglin by regulating proliferation, 
migration, invasion and metastasis. These studies suggest that endoglin behaves as a 
suppressor of malignancy in experimental and human carcinogenesis. In this review, we 
evaluate the implication of endoglin in tumor development underlying studies 
developed in our laboratories in recent years. 
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 INTRODUCTION 
 
The human transforming growth factor- (TGF-β) family comprises more than 
40 structurally related factors including the classical isoforms: TGF-1, -2 and -3, 
activins, and bone morphogenetic proteins (BMPs), among others. These growth factors 
play crucial roles in embryonic development, adult tissue homeostasis and the 
pathogenesis of a number of diseases[1,2]. TGF- signals through heteromeric cell-
surface type I and II Ser/Thr kinase receptors (TRI and TRII) that activate the 
canonical Smad pathway as well as Smad-independent signaling pathways to regulate 
fundamental cellular processes, such as proliferation, differentiation, migration, 
programmed cell death, adhesion, cytoskeletal organization, extracellular matrix 
remodeling and phenotypic plasticity[3-5]. Cancer is a multistep process which involves 
the evolution of a clonal cell population that has escaped from the control of regulatory 
circuits that govern normal tissue homeostasis. Cancer cells accumulate gain-of-
function mutations in oncogenes, that make them independent of growth factor 
stimulated proliferation, and recessive loss-of-function mutations in tumor suppressors, 
that allow evasion of growth inhibitory signals[6]. TGF- is a potent growth inhibitor of 
normal epithelial cells and accumulated evidence indicates that it plays a tumor 
suppressive role in epithelial cancer[7]. Thus, tumor cells evade TGF- growth 
inhibition either by inactivating components of the TGF- signaling machinery, 
including receptors and Smad proteins, or by selectively preventing the TGF- 
cytostatic responses[8]. Paradoxically, TGF- is overexpressed in many human cancers 
and becomes a promoter of malignancy during tumor progression[9-11]. TGF- drives 
tumorigenesis by a variety of mechanisms acting on tumor and stromal cells. TGF- 
stimulates tumor growth by inducing the production of autocrine mitogenic factors. It 
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also promotes tumor cell migration and invasion by inducing an epithelial-mesenchymal 
transition (EMT). EMT is a profound phenotypic conversion by which epithelial cells 
lose their polarity and cohesiveness acquiring motile and invasive properties. EMT 
plays a crucial role in morphogenetic processes during organogenesis, but also 
contributes to pathological situations such as fibrosis and cancer[12,13]. In the stroma, 
TGF- is involved in the generation of activated myofibroblasts from mesenchymal 
precursors, the stimulation of angiogenesis, the suppression of the immune surveillance 
and the promotion of metastasis. 
Endoglin is a TGF- coreceptor that modulates TGF--dependent cellular 
responses. So far, most of research studies on endoglin have focused on its role in 
angiogenesis and vascular remodelling. However, recent data have emerged suggesting 
that inactivation or silencing of endoglin in tumor cells contributes to the deregulation 
of TGF- signaling and malignant progression.     
 
ENDOGLIN AND TGF- SIGNALING 
  
Endoglin structure. Isoforms 
 Endoglin is a type I membrane glycoprotein with a large extracellular domain 
containing several O- and N-glycans, followed by a hydrophobic membrane-spanning 
segment and a short cytoplasmic tail. It is expressed at the cell surface as a disulfide-
linked homodimer[14-17]. The extracellular region contains at the N-terminus an 
orphan domain as well as a zona pellucida (ZP) consensus domain in the 
yuxtamembrane region (Fig. 1a), which is potentially involved in receptor 
oligomerization[18-20]. Within the ZP domain, human endoglin contains an Arg-Gly-
Asp (RGD) motif which is a recognition sequence for integrins[14]. In contrast to the 
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functional TRI and TRII receptors, the cytoplasmic domain of endoglin lacks any 
obvious enzymatic motif, but contains Ser and Thr residues that can be phosphorylated 
by the TGF- receptor kinases (see below and Fig. 1c). In addition, the endoglin 
cytoplasmic tail holds a PDZ-binding motif (Ser-Ser-Met-Ala) at the C-terminus that 
seems to modulate phosphorylation of the neighbouring Ser and Thr residues[21].  
 At least two distinct alternatively spliced isoforms, long (L)-endoglin and short 
(S)-endoglin, are expressed in human and mouse tissues[17,22] (see Fig. 1b). L- and S-
endoglin only differ from each other in the composition of their cytoplasmic domain. 
The human L isoform has a cytoplasmic domain of 47 residues whereas the cytoplasmic 
tail of the S isoform contains only 14 residues (Fig. 1c). Both endoglin isoforms share 
the first 7 juxtamembrane residues of their cytoplasmic tails, but S-endoglin lacks the 
PDZ-binding motif[17,22]. Although significant expression of S-endoglin transcripts 
has been found in some tissues, such as lung and liver[22], L-endoglin seems to be the 
predominant isoform expressed in most of the tissues, particularly in the endothelium, 
and is the focus of most studies on endoglin biology. Therefore, when the general term 
of endoglin is used in this review, it is referred to L-endoglin. 
 
Endoglin in the TGF- receptor complex 
 TGF- growth factors exert their biological effects by binding to a heteromeric 
complex containing the transmembrane Ser/Thr kinase TRI and TRII signaling 
receptors, although it is TRI which determines the signaling specificity within the 
receptor complex[23,24]. The human genome encodes seven TRI (activin-like kinases 
or ALKs 1–7) and five TRII receptors. After binding of the ligand to TRII, it 
activates and transphosphorylates TRI, which subsequently transduces the signal by 
phosphorylating the receptor-regulated Smads (R-Smads). Activated R-Smads associate 
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with a common homolog named Co-Smad (Smad4 in mammals) and these complexes, 
then, translocate into the nucleus where they regulate the transcriptional activity of 
target genes (Fig. 2). TGF- has been found to activate other signalling mediators in a 
Smad-independent manner, including several branches of mitogen-activated protein 
kinase (MAPK) pathways, Rho GTPase signaling pathways and the 
phosphatydilinositol-3-kinase (PI3K)/AKT pathway[3,5].  
The TGF- receptor complex also contains two auxiliary receptors (or type III 
receptors), endoglin and betaglycan, that bind different members of the TGF- 
family[1,25]. Endoglin and betaglycan share a high degree of amino acid sequence 
homology in the transmembrane and cytoplasmic domains[26]. At variance with 
endoglin, no alternatively spliced isoforms have so far been described for betaglycan. 
Betaglycan has been shown to promote high-affinity binding of TGF-2 to TRII, since 
TGF-2 binds TRII with low affinity in the absence of betaglycan[27]. Endoglin binds 
TGF-1, TGF-3 (but not TGF-2), activin-A, BMP-2 and BMP-7 in the presence of 
the signaling TRI and TRII receptors[17,28-30]. In contrast, membrane associated 
endoglin can bind BMP9 in the absence of signaling receptors[31]. Activated ALK5 and 
TRII interact with the extracellular and cytoplasmic domains of endoglin (Fig. 2). 
However, unphosphorylated ALK5 only interacts with the endoglin cytoplasmic 
domain. Upon binding, both ALK5 and TRII phosphorylate Ser and Thr in the 
endoglin cytoplasmic domain and, then, ALK5 but not TRII dissociates from the 
receptor complex[32]. On the other hand, Koleva and coworkers have shown that 
endoglin is a direct substrate of ALK1 in endothelial cells. ALK1 is an endothelial-
specific TRI which preferentially phosphorylates endoglin in Thr residues, although 
this requires previous Ser phosphorylation by TRII[21]. Endoglin phosphorylation 
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seems to play a regulatory role for ALK1-dependent endothelial cell growth and 
adhesion. For a summary of endoglin-binding proteins see Table 1. 
These studies indicate that endoglin is part of the ligand-TRI/TRII complex 
where it likely plays a role in the dynamics of TRI-TRII interactions regulating 
downstream TGF- signaling. Indeed, a large number of laboratories have reported that 
endoglin modulates TGF--dependent responses in different cell types. Accordingly, 
endoglin dysfunction may lead to uncontrolled TGF- signaling activity often resulting 
in human disease.  
  
ENDOGLIN AND THE VASCULAR SYSTEM 
 
Regulation of endoglin expression in endothelial cells 
Endoglin is expressed at low levels in resting endothelial cells, but its expression 
strongly increases in active vascular endothelial cells of inflamed tissues during wound 
healing, in infected tissues, synovial arthritis and psoriatic skin, as well as upon vascular 
injury and tumor angiogenesis[33,34]. In fact, in cultured tumor endothelial cells, 
endoglin expression correlates with the rate of cellular proliferation[35]. TGF- 
potently stimulates endoglin expression in endothelial cells by a Smad-dependent 
mechanism[36,37], but the most suitable stimulus upregulating endoglin expression in 
vessels seems to be hypoxia. The human ENDOGLIN (ENG) gene promoter contains a 
functional consensus hypoxia responsive element for the hypoxia inducible factor HIF-
1[38]. Whereas hypoxia alone stimulates only moderately endoglin transcription, TGF-
1 and hypoxia cooperates to induce a strong stimulation of endoglin expression which 
is mediated by the formation of a transcriptional Smad3/Smad4/Sp1/HIF-1 
multimolecular complex[38]. Also, the cooperative interaction between Sp1 and KLF6 
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transcription factors appears to mediate endoglin transcriptional activation upon 
vascular injury[39]. Interestingly, the functional and physical cooperation between Sp1 
and KLF6 results in upregulation of other injury-related genes such as TGF-1 and 
components of the TGF- signaling complex. In the placenta, it is TGF-3 which 
mediates stimulation of endoglin expression by hypoxia[40]. 
 
Endoglin is a pro-angiogenic molecule 
Endoglin in the blood vessel endothelium is involved in the control of cell 
proliferation, migration and capillary tube formation[41]. Lebrin and coworkers have 
proposed an elegant mechanism for endoglin to regulate angiogenesis by controlling 
TGF- signaling[42].  TGF- can activate two distinct type I receptors ALK1 and 
ALK5 in endothelial cells which have opposite effects on cell behaviour. ALK1 
activation leads to stimulation of endothelial cell proliferation and migration through 
phosphorylation of Smad1/Smad5/Smad8, while ALK5 activation results in inhibition 
of proliferation and migration via phosphorylation of Smad2/Smad3[43,44] (Fig. 2). 
Thus, TGF- controls both the active and maturation phases of angiogenesis[45]. In the 
former phase, endothelial cells degrade the perivascular membrane and migrate into the 
extracellular space where they proliferate and form capillary lumen, while in the 
maturation phase cells stop proliferating and migrating, a reconstituted basal membrane 
surrounds capillary vessels and mesenchymal cells are recruited to the new vessels 
where they differentiate into vascular smooth muscle cells and pericytes[46,47]. 
Endoglin is required for TGF-/ALK1 signaling which indirectly inhibits signalling 
through TGF-/ALK5[42,48]. Therefore, in endothelial cells expressing low levels of 
endoglin, TGF- signals through ALK5 maintaining a resting state in the endothelium. 
However, under hypoxia or increased TGF- levels, endoglin expression is upregulated 
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and TGF- switches to ALK1 signaling promoting angiogenesis. Nevertheless, there are 
conflicting results derived from studies with endothelial cells isolated from Endoglin 
null (Eng
-/-
) embryos. In contrast to the results of Lebrin and colleagues[42], Letarte and 
colleagues have reported that Eng
-/-
 cells display increased TGF- anti-proliferative 
response and TGF-/ALK1 signaling[49].  
On the other hand, based on studies using a transgenic mouse model in which 
the expression of the short S-endoglin isoform was targeted to the blood vascular 
endothelium (S-Eng
+
), we have suggested an anti-angiogenic function for S-
endoglin[22]. Both S-Eng
+
 and Endoglin heterozygous mice (Eng
+/-
) show an 
angiogenic deficient phenotype[41], suggesting that S-endoglin acts as an antagonist of 
the predominant L-endoglin form. Moreover, S-Eng
+
 and Eng
+/-
 mice show 
dysregulated vascular tone and decreased endothelial nitric oxide synthase (eNOS) 
expression[50-53]. Interestingly, the ratio of S/L endoglin expression increases in 
cultured human endothelial cells and vascularized mouse tissues during 
senescence/aging, indicating that S-endoglin may contribute to age-dependent vascular 
pathology[53]. L- and S-endoglin differ in their ability to regulate TGF- cellular 
responses[54] and in modulating TGF- signaling[17,55]. Of note, L- and S-endoglin 
can heterodimerize through their common extracellular domain[22] and, therefore, in 
cells in which both isoforms are coexpressed, S-endoglin may compete for L-L 
homodimer formation. 
Recently, increased endoglin expression has also been found in tumor lymphatic 
endothelial cells with respect to lymphatic endothelial cells of normal tissues[56,57]. 
Interestingly, endoglin expression was upregulated in lymphatic tissue associated with 
lymphangiectasia in a mutant mouse deficient for the regulatory subunits of PI3K[58], 
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suggesting that endoglin expression is inhibited by PI3K and that endoglin may play a 
role in lymph vessel homeostasis.   
  
Endoglin and Hereditary Hemorrhagic Telangiectasia 
 The critical role of endoglin in the vascular system is demonstrated by the 
identification of ENG as the gene mutated in the vascular syndrome Hereditary 
Hemorrhagic Telangiectasia type I (HHT1)[59]. Interestingly, a second gene: ACTIVIN 
RECEPTOR LIKE KINASE (ACVRL1), encoding the ALK1 receptor, was discovered as 
responsible for HHT2[60]. HHT is an autosomal dominant disease with a prevalence of 
about 1 in 10,000 individuals. HHT patients are characterized by arteriovenous 
malformations (AVMs) which range from small capillary dilatations or telangiectases in 
the skin, nasal epithelium, oral mucosa and gastrointestinal tract to large AVMs in lung, 
brain and liver that can lead to internal hemorrhage and stroke[61]. The ENG and 
ACVRL1 loci account for more than 90% of HHT cases. Nevertheless, HHT is linked to 
two other loci for which the genes remain to be identified. In a small proportion of the 
HHT population (about 2%), the pathogenic mutations occur in the MADH4 gene, 
encoding Smad4. The MADH4 gene mutations lead to a combined syndrome of Juvenile 
polyposis (JP) and HHT (see below). Interestingly, all ENG mutations to date are found 
in exons 1 to 12 coding for the endoglin extracellular domain. Most ENG and ACVRL1 
mutations lead to unstable or non-functional proteins, supporting haploinsufficiency as 
the predominant cause of HHT pathogenicity[62].  
Endoglin haploinsufficiency, as the pathogenic mechanism of HHT1, is also 
supported by experiments with animal models. Eng
+/-
 mice develop signs of HHT, such 
as telangectasias, epistaxis and even cerebral arteriovenous malformations[63-65]. The 
strength of these clinical manifestations depends on the animal strain suggesting the 
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existence of modifier genes in HHT[66]. Eng
+/-
 mice also show a reduced angiogenic 
response as well as increased and reduced levels of cyclooxigenase-2 (COX-2) and 
eNOS, respectively[41,51,67]. eNOS and COX-2 produce the vasorelaxant substances 
nitric oxide and prostaglandin E2, respectively and, therefore, endoglin is also involved 
in the regulation of vascular tone[50-52].  
Eng
-/-
 null embryos, on the other hand, die at mid-gestation (E10.5) due to 
circulatory arrest and haemorrhage. These embryos display important alterations in 
cardiovascular development, including incomplete yolk sac vessel branching and 
remodelling, vessel dilatation and cardiac morphogenesis[63,68,69-71]. These and other 
studies suggest a key role for endoglin in early patterning of the heart[72]. 
 
Endoglin as a target for cancer imaging and antiangiogenic therapy  
 The finding that endoglin is overexpressed in vascular endothelial cells of tissues 
undergoing angiogenesis suggested that endoglin detection could be used as a marker to 
analyze angiogenesis and microvessel density (MVD) in tumors. Increased MVD is 
associated with bad prognosis in cancer patients, and the use of endoglin antibodies has 
been found to be the most reliable for MVD measurements when compared to other 
endothelial protein markers[73,74]. Moreover, its association with actively proliferating 
endothelial cells, while it is weakly expressed in quiescent endothelium has focused the 
interest on endoglin as a potential target for cancer imaging in vivo[34]. Studies carried 
out on animal models[75,76] and patients with renal carcinoma[77] clearly show that 
anti-endoglin monoclonal antibodies specifically target the tumor vasculature. In this 
respect, endoglin is a more specific marker for new, immature vessels, unlike other 
endothelial cell-surface markers, such as CD31 and CD34 that are expressed in both 
mature and immature vessels[78]. The anti-endoglin antibodies are useful to detect 
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metastatic tumors that conventional imaging techniques cannot visualize. Also, 
microbubles conjugated with an anti-endoglin antibody have been successfully utilized 
to image (by ultrasounds) the effect of gemcitabine on the vasculature in mouse 
xenografts of human pancreatic tumors[79].  
 Blocking the tumor blood supply by disrupting or preventing the formation of 
new blood vessels has been thought a general strategy to treat cancer[80]. The potential 
of anti-endoglin monoclonal antibodies to be used as a therapeutic anti-angiogenic 
strategy in human cancer has received considerable support from preclinical studies. 
There are excellent reviews addressing this topic[34,74] and, therefore, this matter will 
not be discussed herein. Nevertheless, it is worth to mention that a multicenter phase I 
clinical trial using the anti-endoglin antibody TRC105 is ongoing in patients with 
advanced refractory cancer. The preliminary results support good tolerability and early 
clinical activity of TRC105[81]. 
 
ENDOGLIN IN HUMAN CANCER 
  
Most studies about the involvement of endoglin in cancer have focused on its 
role as a pro-angiogenic molecule and its usefulness as a marker of MVD in tumors. 
However, there is evidence that endoglin modulates cell proliferation, adhesion and 
migration of neoplastic cells suggesting a direct involvement of endoglin in cancer 
either by modulating the response of tumor cells to TGF- or by as yet not completely 
understood TGF--independent mechanisms. In the next sections, we review the current 
data implicating endoglin in tumor progression, mainly in carcinomas. Endoglin has 
also been associated with a hereditary cancer disorder known as juvenile polyposis.  
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Juvenile polyposis syndrome 
 Juvenile polyposis (JP) is an autosomal dominant syndrome characterized by 
multiple hamartomatous polyps occurring throughout the gastrointestinal tract. Patients 
are usually diagnosed within the first decade, but polyps can appear at any age[82,83]. 
The term “hamartomatous” was introduced based on the following histological features: 
dilated cystic glands with retention of mucus and lined by tall columnar epithelium, a 
markedly expanded lamina propia and diffuse chronic infiltration of inflammatory cells, 
to be distinguished from adenomatous polyps[84]. Individuals with JP are at risk of 
developing gastric, colorectal and pancreatic malignancies[85,86]. Mutations in either 
the MADH4 or BMPRIA genes, the latter encoding a transmembrane type I receptor for 
BMPs, are responsible for the majority of JP cases[82,83]. The overall prevalence of 
germline mutations is 20% for MADH4 and 20% for BMPRIA in JP probands[87]. 
SMAD4 mutations are correlated to a high incidence of upper gastrointestinal 
polyps[88,89]. Some JP patients were observed to develop symptoms of HHT, such as 
pulmonary AVMs, that led to the recognition of a combined syndrome JP-HHT which 
is caused by mutations in MADH4 but not in the main genes involved in HHT: ENG and 
ACVRL1[90,91]. JP-HHT patients commonly exhibit AVMs, telangiectases and 
epistaxis as well as gastrointestinal polyps. A recent report has shown that MADH4 
mutations in JP and JP-HHT overlap indicating that there is no apparent molecular 
distinction between JP and JP-HHT[92].  
Also, germline mutations in ENG were found in 2 out of 14 JP patients who did 
not contain MADH4 or BMPRIA mutations[93]. Both JP patients had an early onset of 
the disease (at ages of 3 and 5 years) compared to those without ENG mutations and 
they did not exhibit clinical manifestations or a family history of HHT. The low 
frequency of ENG mutations found in JP patients raised concerns about whether ENG is 
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a susceptibility gene for JP. Thus, a subsequent report aimed to examine the prevalence 
of ENG mutations in JP patients who did not have germline mutations in MADH4 and 
BMPRIA failed to confirm the role of ENG as a gene predisposing to JP[94].  
 
Endoglin alterations in human sporadic cancer 
Only a handful of studies have reported the expression of endoglin in neoplastic 
cells of primary tumors. In prostate cancer, endoglin was detected in epithelial cells of 
both prostatic intraepithelial neoplasia and malignant areas, while cells in normal and 
benign acini were negative[95]. In this study, endoglin staining in prostate cancer cells 
did not correlate with patient/tumor characteristics, including the levels of the prostatic 
specific antigen PSA in serum, Gleason score, tumor stage, and periprostatic invasion. 
In contrast, downregulation of endoglin expression was found in prostate carcinoma cell 
lines associated with malignant progression. Suppression of endoglin expression by 
antisense oligonucleotides enhanced migration and invasion of nontumorigenic prostate 
cell lines, while overexpression of endoglin had the opposite effect[96]. These results 
suggested a role for endoglin as a modulator of migration and invasiveness in prostate 
cancer cells, and were in line with the striking observation that only the ENG gene 
among 4,000 genes was found to be downregulated during detachment of metastatic 
prostate cancer cells[97].  
A report on esophageal squamous cell carcinomas (SCCs) showed that endoglin 
expression is downregulated in both primary tumors and cell lines, and that 
overexpression of endoglin in esophageal SCC cells led to reduced invasiveness and 
tumorigenicity[98]. The mechanisms for endoglin downregulation in esophageal tumors 
include epigenetic silencing by gene methylation and loss of heterozygosity (LOH). 
Previous studies from the same authors had identified that the 9q33-34 region, where 
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the ENG gene was mapped[99], is frequently lost in esophageal cancer[100,101], 
pointing to the existence of a tumor suppressor gene therein.  
Recently, strong evidence pointing to endoglin as a tumor suppressor has been 
obtained in breast cancer[102]. This report shows that lack of endoglin expression in 
primary tumors correlates with ENG gene methylation and poor clinical outcome. 
Furthermore, loss of endoglin expression seems to cooperate with the activated ErbB2 
oncogene to promote migration and invasion of nontumorigenic breast epithelial cells, 
while endoglin overexpression reduces the metastatic ability of the aggressive MDA-
MB-231 carcinoma cell line. These observations indicate that endoglin acts as a 
suppressor of invasion and metastasis in breast cancer, and argue against the report of 
Oxmann and colleagues[103] pointing to a pro-invasive rather than suppressor role for 
endoglin in breast cancer. This latter report shows a direct correlation between enhanced 
endoglin expression and the metastatic abilities of MDA-MB-231 derived cell lines; 
however, no study on primary tumors is presented. A summary of endoglin alterations 
found in sporadic human cancer and their correlation with tumor progression is 
presented in Table 2.  
Endoglin expression has also been found by indirect immunofluorescence in 
hematopoietic malignancies; i.e., 47% of acute myelogenous leukemias (AML), 82% of 
B-cell acute lymphoblastic leukemias (B-ALL) and 7% of T-cell ALL (T-ALL). 
Apparently, endoglin is always expressed by the most immature subtypes of acute 
leukemias and absent in more differentiated ones[73].  
On the other hand, a study in a panel of human tumor cell lines showed that 
endoglin expression is low in carcinoma cells while it is high in sarcoma cells. 
Interestingly, in some carcinoma, melanoma and osteosarcoma cell lines the subcellular 
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location of endoglin was the cytoplasm rather than the plasma membrane[104]. The 
functional significance of this observation remains to be investigated. 
 
Endoglin modulates cell migration and invasiveness  
 It is clear from the above mentioned studies that endoglin modulates adhesion 
and migration of cancer cells. This regulatory function of endoglin was also described 
in different types of nontumorigenic cells, including myoblasts, fibroblasts and 
endothelial cells[105-110]. Regulation of cell migration by endoglin seems to involve 
TGF--dependent as well as TGF--independent mechanisms. Thus, it has been 
reported that endoglin reduces migration of prostate carcinoma cells by activating the 
TRI ALK2, which in turn activates Smad1[111]. Moreover, in prostate carcinoma cells 
expressing low levels of endoglin, the soy isoflavone genistein inhibited migration and 
invasiveness by activating ALK2/Smad1, which suggests a high therapeutic benefit for 
patients with prostate carcinomas expressing low levels of endoglin by treating them 
with genistein[112]. A recent study suggests, however, that ALK2-mediated 
phosphorylation of the endoglin cytoplasmic tail also contributes to prostate cancer cell 
migration through a Smad-independent mechanism[113].  
Endoglin is thought to regulate endothelial cell migration by modulating the 
balance between the ALK5/Smad2/3 and ALK1/Smad1/5/8 TGF- pathways (see 
above). Blobe and colleagues, on the other hand, found that by associating with the 
scaffolding protein GAIP-interacting protein, C-terminus (GIPC) through the 
cytoplasmic PDZ binding motif, endoglin stimulates TGF--induced Smad1/5/8 
signaling and inhibits endothelial cell migration[109]. The same laboratory found that 
endoglin decreases endothelial cell migration by antagonizing TGF--mediated 
extracellular signal regulated kinase (ERK) activation in a manner dependent on its 
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ability to interact with -arrestin2, which results in the internalization of endoglin and 
-arrestin2 in endocytic vesicles[108]. In addition, a recent report point to ALK5-
mediated endoglin phosphorylation on serines 646 and 649 present in the cytoplasmic 
tail as an important mechanism for regulating TGF-1/Smad1/5/8 signaling and 
migration of endothelial cells[110].  
Other studies aimed to identify intracellular proteins interacting with the 
endoglin cytoplasmic domain have reported zyxin and zyxin-related protein 1 (see 
Table 1), two components of the cytoskeleton located at focal adhesions, as the first 
cytosolic proteins that bind endoglin[106,107]. Through these protein-protein 
interactions that could be regulated by phosphorylation[21], endoglin may modulate the 
organization of the actin cytoskeleton and the adhesive properties of the cells by a TGF-
-independent mechanism. The cytoplasmic domain of endoglin (as well as that of 
TRII) also binds Tctex2b, a novel t-complex testis-expressed protein 1/2 (Tctex1/2)-
like protein, which is a member of the dynein light chain protein family involved in the 
transport of cargo, in a retrograde fashion, along the microtubules towards the 
nucleus[114]. 
 
Soluble endoglin in cancer and other diseases 
 The extracellular domain of membrane-bound endoglin can be proteolytically 
cleaved releasing a circulating form of endoglin, named soluble endoglin (Sol-Eng).  
Increased levels of Sol-Eng are linked to the pathogenesis of severe vascular diseases, 
including systemic sclerosis, a condition characterized by early generalized 
microangiopathy with disturbed angiogenesis[115], sporadic brain arteriovenous 
malformations[116], and the pregnancy-specific hypertensive syndrome known as 
preeclampsia[117-119]. High circulating Sol-Eng levels have also been associated with 
 18 
attenuation of the anti-inflammatory response in patients with plasmodium falciparum 
malaria[120], and with poor clinical outcome of biliary atresia patients[121]. Biliary 
atresia is a chronic progressive inflammatory disorder of the extrahepatic and 
intrahepatic biliary system that commonly occurs in children.  
Also, a number of laboratories have found elevated levels of Sol-Eng in body 
fluids from cancer patients with respect to healthy donors (Table 2 and Fig. 3). 
Increased Sol-Eng levels correlate with metastasis in breast cancer and colorectal 
cancer[122,123]. Sol-Eng levels were decreased in patients receiving chemotherapy, 
which reduces the utility of Sol-Eng as a prognostic marker to the long-term follow-up 
of cancer survivors who are not treated with chemotherapy[123]. Elevated levels of 
plasma Sol-Eng also predict decreased response and survival to hormone therapy of 
women with metastatic breast cancer[124]. In prostate cancer, high levels of serum Sol-
Eng correlate with advanced stage of tumor progression, and urinary Sol-Eng seems to 
be a useful marker for diagnosis[125]. In addition, recent reports have shown that 
determination of plasma Sol-Eng in prostate cancer has a predictive value for metastasis 
to the pelvic lymph nodes[126] as well as for increased risk of prostate-specific antigen 
(PSA) recurrence in patients treated with radical prostatectomy and bilateral pelvic 
lymphadenectomy[127]. High levels of Sol-Eng are also present in myeloid 
malignancies that are characterized by a high cellular proliferation rate, such as acute 
myeloid leukaemia and chronic myeloproliferative disorders[128]. Nonetheless, other 
reports on gastric, esophageal and ovarian tumors failed to find Sol-Eng as a valuable 
marker in the assessment of cancer spread[129-133]. 
Sol-Eng contains the binding site for different members of the TGF- 
superfamily, and may act as a scavenger of circulating ligands preventing their binding 
to the functional receptors. Thus, Sol-Eng impairs TGF- signaling interfering with 
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vascular function and inhibiting angiogenesis[117,134].  An intriguing question is the 
source of Sol-Eng detected in cancer patients. Since endoglin levels are higher in tumor 
vessels than in tumor cells, it is thought that Sol-Eng derives from endoglin shedding in 
vascular endothelial cells and that it may represent a surrogate marker of angiogenic 
activity[135]. However, our studies in an experimental model of carcinogenesis (see 
below) suggest that endoglin shedding in tumor cells can also contribute to increase the 
levels of Sol-Eng (Fig. 3).  
On the other hand, the correlation between elevated Sol-Eng levels and poor 
clinical outcome of cancer patients is paradoxical, as Sol-Eng seems to be an anti-
angiogenic agent. In this respect, recent epidemiological studies report that formerly 
preeclamptic women have a reduced incidence of breast cancer. The mechanism 
underlying this observation is unknown, but as preeclampsia is linked to an imbalance 
between pro-angiogenic (such as VEGF) and anti-angiogenic factors, such as Sol-Eng 
and soluble fms-like tyrosine kinase-1 (sFlt-1), persistent mild elevations of anti-
angiogenic Sol-Eng and sFlt-1 may contribute to the inhibition of tumor development 
later in life[136]. 
Recently, it has been reported that the membrane-type matrix metalloproteinase-
14 (MMP14, also called MT1-MMP) is involved in Sol-Eng production[134]. This 
study shows that efficient endoglin shedding requires a direct interaction of endoglin 
and MMP14, suggesting that the origin of Sol-Eng in cancer resides in those sites where 
endoglin and MMP14 are colocalized (Fig. 3).  
 
ENDOGLIN IN EXPERIMENTAL CARCINOGENESIS 
 
The two-stage mouse skin carcinogenesis model  
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Two-stage mouse skin chemical carcinogenesis has become one of the best 
established in vivo models to study the sequential development of tumors[137-139]. 
Concepts such as tumor initiation, promotion and progression emerged from this 
model[140], that has been classically utilized in environmental cancer studies to test 
chemicals that may cause, prevent or cure cancer[141]. Nowadays, the mouse skin 
chemical carcinogenesis system is also used to evaluate the impact of genetic 
background and genetic manipulation on tumorigenesis. Tumor induction in two-stage 
carcinogenesis involves a single sub-carcinogenic dose of a carcinogen initiator, such as 
7,12-dimethylbenz(a)anthracene (DMBA). This event alone does not give rise to tumors 
unless followed by repeated application of a tumor promoter, such as 12-O-
tetradecanoylphorbol-13-acetate (TPA). This protocol gives rise to the appearance of 
multiple benign papillomas representing clonal outgrowths of epidermal keratinocytes 
with initiating mutations in the Hras1 gene[142]. Papillomas can progress to malignant 
SCCs; however, there is evidence that papillomas are heterogeneous in their potential 
for malignant conversion. Thus, two entities named as low-risk and high-risk benign 
papillomas with differing rates of premalignant progression have been defined[143]. 
SCCs are highly vascularized inward invasive lesions that can be classified into well 
differentiated (grade I), moderately differentiated (grade II) and poorly differentiated 
(grade III/IV) according to the degree of squamous differentiation[144]. This latter 
group includes the highly aggressive spindle cell carcinoma (SpCC) type of tumor 
formed by elongated or spindle-shaped cells that have elicited an irreversible epithelial-
mesenchymal transition[145] (Fig. 4). Progression from papillomas to SCCs is 
associated with trisomies of chromosomes 6 and 7 (the Hras1 gene is located on 
chromosome 7), as well as inactivating mutations in Trp53 and increasing aneuploidy 
and dysplasia[137,145]. The SCC-SpCC transition correlates with increased ratio of 
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oncogenic versus normal Hras1 expression and loss or misregulation of the Ink4 locus 
encoding the cell cycle inhibitors p16Ink4a, p15Ink4b and p19Arf[145]. Interestingly, 
p15Ink4b mediates the growth inhibitory response induced by TGF-1 in epithelial 
cells[8], and SpCC cells do not respond to TGF--induced growth inhibition. 
TGF- is an important regulator of epidermal homeostasis. TGF- was 
documented to inhibit proliferation but promote differentiation of keratinocytes, 
suggesting that it primarily acts as a tumor suppressor in skin carcinogenesis[146]. 
Indeed, a biphasic role for TGF-1 as a suppressor and a promoter of carcinogenesis 
(see Fig. 4) was demonstrated in transgenic mice overexpressing the growth factor in 
differentiating epidermal keratinocytes[147]. TGF-1 is thought to inhibit proliferation 
and induce apoptosis during initiation and early stages of carcinogenesis. At later 
stages, elevated levels of TGF-1 stimulate malignant progression by promoting tumor 
cell migration, invasion and metastasis in a cell-autonomous manner, and by influencing 
the tumor micoenvironment facilitating angiogenesis and evasion of the immune 
system[9,10]. TGF-1 seems to be the physiological agent involved in pushing the 
SCC-SpCC transition during mouse skin carcinogenesis, likely in cooperation with the 
Hras1 oncogene[145].   
 
Endoglin studies on mouse skin carcinogenesis  
 When Eng
+/-
 heterozygous mice were subjected to two-stage skin carcinogenesis 
with DMBA and TPA, these animals developed a lower number of  tumors than control 
Eng
+/+
 mice, but the frequency of papilloma-carcinoma conversion and the incidence of 
poorly differentiated SCCs was vastly increased[22,148]. Accelerated malignant 
progression in Eng
+/-
 mice occurred in adverse conditions, as these animals exhibit a 
deficient angiogenic switch[41]. The carcinogenic phenotype of Eng
+/-
 mice was 
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identical to that of mice with targeted expression of TGF-1 to the epidermis[147], 
mirroring the dual role of TGF-1 in carcinogenesis as a tumor suppressor and 
promoter. These results suggested that endoglin contributes to epidermal homeostasis 
by attenuating the growth inhibitory response elicited by TGF- in basal keratinocytes, 
which is the compartment expressing endoglin in normal epidermis[148]. This 
hypothesis was confirmed by demonstrating that indeed endoglin inhibits the TGF-
/ALK5/Smad2/3 signaling pathway in keratinocytes[149]. In addition, the tumor 
phenotype of Eng
+/-
 mice pointed to a role for endoglin as a suppressor of malignancy at 
late stages of skin carcinogenesis. 
The analysis of endoglin expression in chemically-induced mouse skin tumors 
and cell lines revealed a novel mechanism for inactivation of endoglin in tumor cells by 
shedding. The truncation of membrane-associated endoglin releasing Sol-Eng into the 
stroma and blood stream was associated with the SCC-SpCC transition[149] (Fig. 4). 
Endoglin expression studies also showed that the S-endoglin isoform is neither 
expressed in normal skin nor tumors and consequently does not play any role in skin 
carcinogenesis.  
The functional consequences of inactivating membrane endoglin in tumor cells 
were approached by using short hairpin RNA (shRNA) interfering technology. 
Downregulation of endoglin expression in cultured SCC cells induced the constitutive 
activation of the ALK5/Smad2/3 signaling pathway independently of ligand binding 
leading to EMT and a SCC-SpCC conversion in vivo[149]. In this respect, it should be 
mentioned that a role for endoglin in embryonic EMT during cardiac valve formation 
was also simultaneously reported[150]. These results unequivocally demonstrated that 
endoglin acts as a suppressor of malignancy during mouse skin carcinogenesis. 
Likewise, since endoglin knockdown in SCC cells was also linked to reduced cell 
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growth and delayed tumor latencies, we postulated that inactivation of membrane 
endoglin in tumor cells exerts a strong selective pressure during SCC-SpCC progression 
by priming cells that have lost the TGF- anti-proliferative response. This could be the 
reason why loss of the TGF- growth inhibitory response co-segregates with the spindle 
tumor phenotype[151]. 
Recent results suggest a novel regulatory function for endoglin on mouse skin 
carcinogenesis. TGF-1 stimulates Hras1 gene expression in transformed keratinocytes 
by a Smad-independent mechanism involving the Ras/ERK signaling pathway. 
Interestingly, endoglin not only inhibits basal and TGF--mediated ERK signalling 
activity but protect cells from Hras oncogene transformation (Santibáñez et al., 
manuscript submitted for publication). This finding unveil a new aspect for the 
suppressor role of endoglin during mouse skin carcinogenesis, a model in which Hras1 
activation drives not only tumor initiation but also malignant progression[138,145].     
    
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Endoglin by virtue of its pro-angiogenic activity has become a well established 
marker to analyze angiogenesis and MVD in tumors. It also has revealed its potential as 
a target for cancer imaging and anti-angiogenic therapy. New insights have emerged 
recently on the role of endoglin as a tumor suppressor during progression to 
malignancy. However, a greater effort is needed to unravel the clinical significance of 
endoglin expression in human primary tumors by studying larger cohorts of patients and 
using a better classification of tumors. Whereas some reports suggest that the basis for 
the involvement of endoglin in tumor cell migration and invasiveness resides on its 
ability to modulate TGF- signaling, in most cases the precise mechanism for which 
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endoglin regulate these processes is unknown. In particular, studies on the interaction of 
endoglin with components of the cytoskeleton and on its regulation of TGF--
independent cell responses should be continued.  
The assigned role of endoglin as a suppressor of malignancy in epithelial cancer 
raises important questions for HHT patients, which inherit an inactivated ENG allele by 
the germline. The studies on Eng
+/-
 mice predict that HHT1 patients might be protected 
for tumor formation, but tumors arising in these individuals will be prone to progress 
rapidly to malignant carcinomas. Nonetheless, epidemiological data for cancer 
incidence in HHT1 patients is lacking at the present time.  
Further investigations are also required to solve the contradiction of Sol-Eng 
being a bad prognostic factor in some types of human cancer while having an anti-
angiogenic function in preeclampsia and other vascular diseases. An explanation for this 
paradox might be that production of Sol-Eng is a late event during carcinogenesis (see 
Fig. 4) and, therefore, its anti-angiogenic activity may be irrelevant for tumor growth at 
this stage. Nevertheless, it should be of interest to study the effects of Sol-Eng on tumor 
cell behaviour and on the competence of stromal cells (cancer-associated fibroblasts or 
CAFs, inflammatory cells) to sustain tumor growth (Fig. 3). On the other hand, there are 
no studies addressing the role of membrane-associated endoglin expressed in the 
stromal compartment. In particular, whether endoglin regulates the activity of CAFs to 
promote tumor growth and progression should be investigated in the next years.  
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Endoglin TGF-β TβRI TβRII Other 
TABLE 1
Endoglin interacting proteins
 
domain superfamily 
ligands 
proteins 
Extracellular 
domain 
TGF-β1 
TGF-β3 
activin A 
BMP-2  
BMP-7  
ALK1  
ALK2  
ALK3  
ALK5  
ALK6
TβRII 
ActRII 
BMPRII
 
BMP-9  
Cytoplasmic 
domain 
 ALK1  
ALK5
 Zyxin 
ZRP-1     
β-arrestin2 
Tctex2β 
TABLE 2
Changes in endoglin expression found in sporadic human cancer
Tumor type Endoglin expression Biological source Correlation with/ 
comments 
References
 
Leukemia 
 
High levels of Sol-Eng 
 
Serum  
 
AML, CML [128]
CRC High levels of Sol-Eng Serum Metastasis [123]
Breast 
carcinoma 
High levels of Sol-Eng 
 
Serum/plasma  
 
Metastasis/reduced 
clinical  benefit rate to 
[122-124]
 
 
Downregulated 
 
Upregulated  
 
 
Primary tumors 
 
MDA-MB-231 
derived cell lines 
 
hormone therapy 
 
Poor clinical outcome 
 
Metastasis 
[102]
[103]
Prostate 
carcinoma
Positive in PIN and 
cancer cells
Primary tumors No correlation with 
clinical parameters
[95]
    
 
High levels of Sol-Eng 
 
 
 
 
 
 
 
Plasma 
 
 
 
Serum/urine 
 
  
 
Metastasis/PSA 
recurrence after radical 
prostatectomy    
 
Tumor 
progression/higher 
tumor volume 
[126,127]
[125]
AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CRC, colorectal 
cancer; Sol-Eng, soluble endoglin; PIN, prostatic intraepithelial neoplasia 
 
 
Downregulated 
 
Cell lines 
 
Metastasis   [96]
 
Esophageal 
SCC 
 
Downregulated 
 
Primary tumors 
and cell lines 
 
Tumor progression  [98]
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FIGURE 1. Endoglin structure and isoforms. (a) Schematic representation of endoglin structure.
The location of the integrin-binding RGD motif and PDZ-binding motif are indicated. ZP, zona
pellucida (b) Diagram representing the alternate splicing mechanism originating L- and S-
endoglin. The intron located between exons 14 and 15 (in blue), which contains a TAG stop
codon, is transcribed into the S-endoglin mRNA, but is spliced out to yield the L-endoglin
transcript. (c) Comparison of human L- and S- endoglin cytoplasmic domains. Identical amino
acids are in grey. L-endoglin is phosphorylated at Ser/Thr residues by TβRII, ALK1 and ALK5.
TM, transmembrane.
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FIGURE 2. Hypothetical model for endoglin regulation of TGF-β dependent and independent
cell responses. Endoglin modulates TGF-β signaling by interacting with TβRI (ALK5 and
ALK1) and TβRII through its extracellular and cytoplasmic domains. The endoglin cytoplasmic
domain interacts with β-arrestin, Tctex2b, zyxin and ZRP-1 proteins. Through these
interactions endoglin could mediate F-actin rearrangements, cell adhesion and migration, as
well as protein transport via endocytic vesicles.
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i f l bl d li i d i ibl i h l iFIGURE 3. Generat on o so u e en og n n tumors an ts poss e act ons. T e proteo yt c
cleavage of membrane endoglin (m-Eng) to release soluble endoglin (Sol-Eng) can occur in the
primary tumor as well as in the stroma and blood vessels. It has been shown that Sol-Eng inhibits
angiogenesis, but its effects on the behavior of tumor cells, cancer-associated fibroblasts (pink)
and inflammatory cells (blue and purple) have not been tested yet.
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FIGURE 4. Schematic representation of the different stages of chemical mouse skin
carcinogenesis. The keratinocyte in the epidermis colored in brown represents a cell with Hras1
mutation initiated by DMBA. Mutated Hras1 gene expression increases during tumor progression.
TGF-β1 behaves as a tumor suppressor at early stages of carcinogenesis, but promotes tumor
progression at later stages. Proteolysis of m-Eng to produce Sol-Eng mainly occurs during the
transition from squamous cell carcinomas (SCCs) to spindle cell carcinomas (SpCCs). m-Eng
which inhibits TGF-β signaling in keratinocytes behaves as a suppressor of malignancy at later
stages of carcinogenesis.
